PT  - JOURNAL ARTICLE
AU  - Fan, Xiao
AU  - Wynn, Julia
AU  - Shang, Ning
AU  - Liu, Cong
AU  - Fedotov, Alexander
AU  - Hallquist, Miranda L.G.
AU  - Buchanan, Adam H.
AU  - Williams, Marc S.
AU  - Smith, Maureen E.
AU  - Hoell, Christin
AU  - Rasmussen-Torvik, Laura J.
AU  - Peterson, Josh F.
AU  - Wiesner, Georgia L.
AU  - Murad, Andrea M.
AU  - Jarvik, Gail P.
AU  - Gordon, Adam S.
AU  - Rosenthal, Elisabeth A.
AU  - Stanaway, Ian B.
AU  - Crosslin, David R.
AU  - Larson, Eric B.
AU  - Leppig, Kathleen A.
AU  - Henrikson, Nora B.
AU  - Williams, Janet L.
AU  - Li, Rongling
AU  - Hebbring, Scott
AU  - Weng, Chunhua
AU  - Shen, Yufeng
AU  - Crew, Katherine D.
AU  - Chung, Wendy K.
TI  - Penetrance of breast cancer genes from the eMERGE III Network
AID  - 10.1101/2021.04.24.21255936
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.24.21255936
4099  - http://medrxiv.org/content/early/2021/04/26/2021.04.24.21255936.short
4100  - http://medrxiv.org/content/early/2021/04/26/2021.04.24.21255936.full
AB  - We studied the penetrance and clinical outcomes of seven breast cancer susceptibility genes (BRCA1, BRCA2, TP53, CHEK2, ATM, PALB2 and PTEN) in almost 25,000 participants unselected for personal or family history of breast cancer. We identified 420 participants with pathogenic or likely pathogenic variants, and 147 were women who did not previously know their genetic results. Out of these 147 women, 32 women were diagnosed with breast cancer at an average age of 52.8 years. Estimated penetrance by age 60 years ranged from 18-44%, depending on the gene. Within the first twelve months after genetic results disclosure, 42% of women had taken actions related to their genetic results and two new breast cancer cases were identified. Our study provides population-based penetrance estimates for the understudied genes, CHEK2, ATM, and PALB2, and highlights the importance of using unselected populations for penetrance studies. It also demonstrates the potential clinical impact of genetic testing to improve healthcare through early diagnosis and preventative screening.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the NHGRI through the following grants: U01HG8657 (Group Health Cooperative/University of Washington); U01HG8685 (Brigham and Women's Hospital); U01HG8672 (Vanderbilt University Medical Center); U01HG8666 (Cincinnati Children's Hospital Medical Center); U01HG6379 (Mayo Clinic); U01HG8679 (Geisinger Clinic); U01HG8680 (Columbia University Health Sciences); U01HG8684 (Children's Hospital of Philadelphia); U01HG8673 (Northwestern University); U01HG8701 (Vanderbilt University Medical Center serving as the Coordinating Center); U01HG8676 (Partners Healthcare/Broad Institute); and U01HG8664 (Baylor College of Medicine).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board approval was obtained at all ten eMERGE III clinical sites, including Cincinnati Children's Hospital Medical Center, Children's Hospital of Philadelphia, Columbia University, Geisinger Clinic, Harvard University, Mayo Clinic, Meharry Medical College, Northwestern University, Kaiser Permanente Washington with the University of Washington and the Fred Hutchinson Cancer Research Center, and Vanderbilt University Medical Center.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data sets summarized here will be publicly available in the dbGaP repository under phs001616.v1.p1 and pre-dbGaP submission access can also be requested on the eMERGE website. https://emerge-network.org